

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087669 A1

(51) International Patent Classification⁷: **C07D 215/42**,
215/38, 239/28, 239/72, A61K 31/47, 31/505, A61P 3/04,
25/00, 9/00, 43/00

(21) International Application Number:
PCT/JP2004/004624

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/458,530 31 March 2003 (31.03.2003) US
60/495,911 19 August 2003 (19.08.2003) US
60/510,186 9 October 2003 (09.10.2003) US
60/530,360 16 December 2003 (16.12.2003) US

(71) Applicants (for all designated States except US): **TAISHO PHARMACEUTICAL CO. LTD.** [JP/JP]; 24-1, Takata 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **ARENA PHARMACEUTICALS INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, California, 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SEKIGUCHI, Yoshinori**, [JP/JP]; c/o Taisho pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **KANUMA, Kosuke**, [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **OMODERA, Katsunori**, [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **BUSUJIMA, Tsuyoshi**, [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **TRAN, Thuy-Anh**, [US/US]; 4833 Fairport Way, San Diego, California, 92130 (US). **HAN, Sangdon**, [KR/US]; 9953 Fieldthorn Street, San Diego, California, 92127 (US). **CASPER, Martin**, [US/US]; 6341 Peach

Way, San Diego, California, 92130 (US). **KRAMER, Bryan, A.**, [US/US]; 8863 Duncan Road, San Diego, California, 92126 (US). **SEMPLE, Graeme**, [GB/US]; 15920 Camino Cordoniz, San Diego, California, 92127 (US). **ZOU, Ning**, [CN/US]; 9829 Fieldthorn St., San Diego, California, 92127 (US).

(74) Agents: **ASAMURA, Kiyoshi** et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo, 1000004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF



(57) Abstract: The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.



WO 2004/087669 A1